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Abstract
Background: This study explores young people’s daily experiences of living with Juvenile Idiopathic Arthritis (JIA) and
their thoughts, beliefs and feelings related to the biological drug Etanercept, prescribed as part of their treatment.
Methods: An Interpretive Phenomenological approach was used to allow in-depth examinations of the young people’s
personal accounts of their lived experiences. Data were obtained from 6 young people between the ages of 10–13
years, from one tertiary institution’s Paediatric Rheumatology department using audio-taped open-ended interviews.
Results: The transcripts yielded seven thousand words of data and two hundred significant statements, which were
reduced to five themes; 1) Who understands me, 2) Medicines and injections, 3) Challenges of schooling and friendships,
4) Being different, and 5) Exclusion from sports. There were marked similarities between the young people’s statements;
however, there were also some striking differences. The theme ‘Who understands me’ yielded the biggest section of data,
but also produced the biggest disparity between the young people. Two patients were very clear that they thought
everyone ‘understands’, whilst two other patients held the belief that ‘no one understood’. This paper explores these
statements in further detail.
Conclusions: The findings from this study can give healthcare professionals novel insight into the likely reactions to-
treatment for JIA and, through this, enable them to offer improved support, education and early intervention before
these issues become a concern. This study also provides insight into the emotional resilience of young people with JIA.
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Background
Juvenile Idiopathic Arthritis (JIA) is one of the most com-
mon autoimmune diseases of childhood, and is one of the
leading causes of childhood-acquired disability. It is increas-
ingly recognised that JIA has major health consequences
that impact on social, educational and family life through-
out the teenage years and well into adulthood [1, 2]. Over
the past decade the advent of new therapies for paediatric
rheumatic conditions, particularly the introduction of bio-
logical agents, has radically changed the management of pa-
tients with JIA. Etanercept, a tumour necrosis factor
(TNF)-alpha receptor antagonist (anti-TNF), was the first
biological agent approved for use in JIA, and is given either
as a twice or once weekly subcutaneous injection [3]. Ac-
cording to the UK National Institute of Clinical Excellence
(NICE) guidelines published in 2002 only young people
who have failed Methotrexate treatment (either due to lack
of efficacy or intolerability) may be prescribed Etanercept
[4]. However, this medication provides no guarantee of suc-
cess; initial studies suggest approximately 70-75 % of young
people improve on biological therapies and the response
rate is lower than this in some subtypes of JIA [5, 6].
Although the biological efficacy of Etanercept is estab-
lished, how children and young people feel when receiv-
ing the therapy is unexplored. Some research has been
conducted to explore the psychological responses to suc-
cess or failure of drug treatment in adult patients, but
few studies so far have focussed on young people receiv-
ing biologic therapies and how they assess its impact.
Hence, the aim of this study was to understand the
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young people’s perspectives of living with JIA specifically
receiving therapy with biologic agents.
Methods
Interpretive Phenomenology was the chosen method for
this research, as the goal of phenomenology is to study
how people make meaning of their lived experience and
to answer the question ‘what does it feel like?’ [7] The
methodology chosen supports the desire to gain greater
insight to the lives of patients and the impact their ill-
ness has upon them, inviting them to offer descriptions
of their experiences and discuss their views of the medi-
cation they are receiving. Phenomenological studies typ-
ically involve small numbers of participants, often no
more than ten.
Patient population
This study was a sub-study of the Childhood Arthritis
Response to Medication (CHARMS) Study [8, 9]. Full
ethical approval was sought and full informed parental
consent and young person assent were obtained for all
the subjects. The CHARMS study collects data in two
arms, a prospective and retrospective group, studying
biological mechanisms of, and psychological responses
to, success or failure of drug treatment in JIA. As part of
this wider sponsored study, this project provided a
mechanism whereby further in-depth qualitative data
could be collected from a subset of subjects.
Data collection
Data were obtained from young people attending a tertiary
care Paediatric Rheumatology Department, using audio-
taped open-ended semi-structured interviews aided by
spider diagrams drawn by the young person. Purposive
sampling captured young people who were receiving their
first anti-TNFmedication. The six participants who were
approached met the inclusion criteria of a) having a diag-
nosis of JIA, b) on Etanercept, c) ten years of age or over.
There were no refusals or withdrawals. All young people
chose to be interviewed on their own. Each interview had
the same structure, and began by asking the young person
how they felt about their arthritis, and then asking them
to either draw/write (Fig. 1) or discuss this in more detail.
Each interview naturally progressed as young people
talked about what was important to them. Each interview
was between 30–60 min long.
Analysis
Analysis of the data was undertaken using Colaizzi’s seven
stage process; this method was chosen due to its compati-
bility with the interpretive approach [10, 11]. The first
stage of Colaizzi’s (1978) process is to transcribe the tapes
word for word and then to read and re-read the typed nar-
ratives. Each transcript is analysed to identify significant
statements that told each participant’s story of their lived
experience [12]. At this stage it is important to highlight
as many statements as possible within each transcript and
to be observant for the manner in which each statement
was iterated, “empathetically dwelling” with each experi-
ence [11]. Formulated meanings were devised for each
participant and arranged on a separate sheet; this ensured
the young person’s own words constituted the formulated
meaning. Throughout the whole process, constant refer-
ence was made back to the young person’s spoken words
to maintain credibility. Eventually five themes were identi-
fied with all young people having a voice in each theme.
When the seventh stage of data analysis was approached
(return to the subject and check they agree with the
Fig. 1 A spider diagram drawn by one of the young participants. This is one of the spider diagrams written by one of the young people. The young
person used this space to write about how their arthritis makes them feel. The sticker in the middle was for the young person to visualise themselves in
the middle, and the words written around the outside describe how they feel and their concerns. Some examples of the text written here include such
comments as; ‘Isolated, fed up, angry, bored and depressing’, ‘I feel responsible for my mum smoking’ and ‘JIA gets in the way of sports and social life’
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findings) the lead researcher was concerned about ethical
implications of returning the text to the young people, for
concern of stirring up emotions. It was therefore decided
to produce a newsletter, to encompass an overview of all
the young people’s comments, but also to be a resource of
further advice and help, such as websites. This way the
young people, who had been going through a particularly
difficult time, should not be reminded of how they felt, but
in keeping with Colaizzis (1978) view that they the young
people are co-researchers and should be involved, they
would still have some feedback from their participation.
Results
Interview data
The 6 participants recruited were aged 10–13 years, 2 fe-
male, 4 male, all Caucasian, had English as first language,
and disease duration of 5–11 years. All patients were re-
ceiving both Methotrexate and Etanercept, and this was
their first anti-TNF therapy. Two young people had poly-
articular JIA, 2 had systemic JIA and 2 had extended oli-
goarticular JIA by internationally agreed classification
criteria [13] (Demographics are shown in Additional file 1:
Table S1). In relation to the decision to include two young
people with Systemic JIA, it is worth noting that these
children now had polyarticular disease with no recent sys-
temic features. This study aimed to be inclusive, capturing
young people’s views on their arthritis and biological medi-
cation, so the view of these individuals was felt to be just
as valid as others, although we acknowledge that prior ex-
perience in those with sytemic JIA may be different from
those with Polyarticular JIA at onset. All patients had
started Etanercept within a year (range 2–10 months) of
this study. At the time of interview, the number of current
active joints ranged from 1–9 in all the young people, none
were in remission. One of the young people had previously
had a hip replacement, but there were no other co-
morbidities, such as uveitis or pain syndromes. As this was
a small indepth study looking at young peoples thoughts,
Health Related Quality of Life data was not collected, how-
ever all young people had significant disease of a minimum
of five years of disease duration and the need to attend at
least 3 monthly clinics. The comments, thoughts, percep-
tions and feelings of the young people fell into 5 themes,
which for this analysis were called: who understands me?;
medicines and injections; challenges to schooling and
friendships; being different; and exclusion from sports, es-
pecially physical education (PE). These data are each pre-
sented here in turn.
Themes
Who understands me?
This section of data yielded the largest cluster and showed
the biggest disparity between the young people. Two of the
young people voiced the opinion that others don’t
understand what it is like to have arthritis, whereas the
other four talked about some people understanding, such
as close family. For example, Patient 1 said “in school they
didn’t really understand, and then my mum got this video
and then everyone started understanding and stopped ask-
ing questions”. Patient 2 said “my five year old sister under-
stands what I’ve got wrong with me”. In this section
Patient 3 said “I feel angry, angry all the time, angry that
no-one understands me, it’s very lonely to have arthritis”;
patient 4 said “it’s sad and depressing’cuz people just stay
away from you, they don’t know that people and young
kids can get it too, they don’t believe you and think you are
making it up because they only know about old grannies”.
Patient 5 said “no one knows what I’ve been through”.
Medicines and injections
This theme revealed marked similarity in the young people’s
comments. Five of them remarked on positive differences
between Etanercept and their previous therapy, and whilst
injections were highlighted as a drawback by all of the
young people, some coped better than others. Patient 1
commented that “the Etanercept doesn’t sting as much and
the needles are smaller”, Patient 6 said that “I have to inject
it into myself, it doesn’t bother me, I used to inject my
Methotrexate and Anakinra, so it’s all the same”. Patient 2
seemed confused about side effects by saying that “this
drug’s ok, the methotrexate never worked’cuz I was always
sick (made me vomit)” and, Patient 5′s observation was that
“I don’t want to give it to myself”. Finally, Patient 3′s state-
ment was that “the Etanercept’s useless’cuz it doesn’t work
for me, I’m just a guinea pig, you get told all these things
will work, they don’t, nothing works”.
Challenges to schooling and friendships
None of the patients could separate schooling and peer re-
lationships from their arthritis; all faced challenges with
their education and/or friendships. Some comments were
specific to actual school facilities and the environment. Pa-
tient 1 said “I have a laptop because I can’t write quickly”
and Patient 4 said “it’s hard to get around the school when
you are on crutches as the corridors are too thin”. Patient
6 and Patient 3 talked more about friendships at school,
Patient 6 “my mates are really good, they know what is
wrong with me” whereas Patient 3 said “I feel lonely, it af-
fects your friendships, secondary school is so different,
they even have a disability office, loads of wheelchairs and
special glass lifts–makes you feel sad”. Patient 5 men-
tioned the effects of being absent: “I didn’t go to school
for about 6 months, I didn’t do any work, I get low school
reports because I’m not there”.
Being different
This theme yielded much of the strong emotion that was
expressed, as illustrated from each of the following
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significant statements. Patient 1: “it’s annoying to see other
children running about and you think I wish I was there”.
Patient 6: “I wish I didn’t have it, I always wonder what I
would be like, how my family would treat me differently”.
Patient 3: “it’s always there in your mind that you are not
normal”. Patient 2: “you have to do exercises every night
which hurt”. Patient 4: “people treat you differently, the idea
of being different is upsetting, well not that different, being
different is quite a big thing, I don’t want extra help as I
don’t want to be more different, people automatically think
you can’t do things and you can’t be bothered to say you
can, so you end up sitting watching and feeling sad”. Patient
5: “you don’t feel confident to socialise with your friends,
you just feel different, like you don’t really fit in, makes you
feel isolated and fed up”.
Exclusion from sports, especially Physical Education (PE)
lessons
This theme, whilst being the smallest cluster of signifi-
cant statements, had a premise universal for all six
young people–that of not being able to fully participate
in sports, especially physical education (PE). Patient 4
commented that “I get out of PE as I can’t do it at times,
and people think I just use it as an excuse, I now go to
the library and stamp books instead”. Patient 6 said “I
can’t do rugby and football now I’ve had both my hips
replaced” and Patient 3 reflected “no point even talking
about football anymore, I can’t wear my kit as I can’t
play, I can’t even do it now, I wouldn’t be good, not as
good as if I didn’t have this–the arthritis, ‘my devil’, no
point bringing friends back to the house, we used to play
football in the garden, it’s what we used to do, but until
I’m normal again, I don’t want to keep making excuses”.
Discussion
In this study, an in-depth open but semi-structured inter-
view approach has facilitated the uncovering of many
mixed emotions of young people with arthritis. ‘Who un-
derstands me’ was a particularly complex theme, as the
term ‘understanding’ covers many aspects of a chronic dis-
ease. One of the points raised in this section was the view
that ‘no one knows kids can get arthritis too because they
only know about old grannies’. This created frustration in
trying to explain to friends and teachers about their illness.
This is an issue raised by Hutchinson and Hall 2007 [14].
In the theme of ‘Medicines and Injections’, most of the
young people were positive about their Etanercept therapy.
This supports the study by Marshall et al. [15], in which
the majority of adult patients were very positive about the
effects of their treatment. Whilst they found positive state-
ments were related to patients’ perceived improvement in
quality of life, in our present study young people were
more positive about the difference in side effects between
Etanercept and their previous therapy, Methotrexate. This
issue is not discussed by Marshall et al. 2004 [15]. One
issue that arose for one patient was being ‘promised’ that
the drug would work, and the patient feeling it hadn’t.
This supports Marshall et al. 2004 [15], who state that
some patients in their study found that anti-TNF therapy
did not live up to their high expectations.
‘Challenges to schooling and friendships’ covered many
different issues. All of the young people mentioned missing
school to go to hospital. The advice booklet “When a
Young Person has Arthritis: for teachers” [16] specifically
highlights provision and support a young person may need
at school; however, it does not mention the young person’s
fear of asking for these provisions. Whilst some young
people may be happy to have a laptop when they found
handwriting was difficult, some of the others in the study
were quite concerned about extra assistance making them
appear different. The issue of transition from primary to
secondary school was mentioned by three of the young
people, who all alluded to the negatives of moving from
primary to secondary, and were anxious about this change.
Three of the young people indicated feelings of ‘loneliness’;
one of the tasks of adolescence is ‘making friendships’ and
finding out where you fit with your peer group and it was
these young people recently moved to secondary school
who were especially struggling with their friends.
In the theme defined as ‘Being different’ all of the young
people acknowledged that they felt ‘different’ from peers
and highlighted that they did not wish to feel this. Whilst
‘feeling different’ does not have to be a negative emotion,
in the present study it was felt that these six young people
all saw it as such: ‘feeling different and then sad’ or ‘feel
different from how a normal person feels’. These com-
ments could be a concern to health care professionals and
lead them to consider whether these young people need
extra support [17].
When discussing sports and PE lessons, the message
was the same from all the subjects: we do not participate
in sport as our friends do. Paradoxically, there are many
reasons why young people with JIA need to do daily ex-
ercises, including to help maintain a better range of joint
movement and mobility, to prevent contractures, to pre-
vent osteoporosis and to build up muscle strength [18],
yet often they do not take part in school PE.
General applicability
There are three particular areas which it is felt that we as
health care professionals could improve upon: firstly, tran-
sition between primary and secondary (or ‘high’) school.
Here, simple measures may help, such as discussing this
transition in advance when young people are still at pri-
mary school, reviewing the role of the school nurse in
terms of support, and highlighting for families what a diffi-
cult time this can be. Exclusion from sports, especially PE,
was the second issue highlighted by all of the children, not
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just the males, and it is the responsibility of the clinician
to identify those not fully partaking in PE at routine ap-
pointments, to highlight the benefits of joining in PE (both
physically and psychologically) and to encourage young
people to talk about the difficulties they face with sport.
The health professional could suggest to the school that
modifying the PE class so that the young person with JIA
can participate to the best of their ability, may be better
than singling them out and giving them another unrelated
task to do. Finally, the high expectations of new therapies
is the third area identified. Clinicians can help by begin-
ning to discuss changing therapies early on (before the first
therapy stops working), to aim to balance high hopes with
realistic expectations and to offer young people the oppor-
tunity to talk to other young people with similar condi-
tions on similar therapies.
Overall this study has highlighted that young people
with JIA can feel isolated and feel that people do not
understand them. It is therefore important for the health
professional to acknowledge this and offer psychological
support early to help young people cope better.
This study has some limitations. “Due to different popu-
lations and cultural differences concerning priorities in
different countries, this study may have limited applicabil-
ity outside the United Kingdom.” Qualitative studies are
typically small in number, but rich in depth. The study did
not have the breadth to be able to further examine differ-
ences between the young people’s assessments of the ef-
fects of disease duration, adolescent development stage or
their individual support networks or collect such data as
quality of life and pain scores. The patients seen at our
tertiary centre do have severe disease as can be seen in
these young people, for example having bilateral hip re-
placements, and thus their comments may not be typical
of a less severe cohort of young people with JIA. Including
more males than females and two children with polyarti-
cular systemic disease was purely by chance. We recognise
that these 6 cases do not reflect the prevalence of subtypes
or gender of these forms of JIA in the population. Given
the small sample size we were not able to analyse the ef-
fect of gender or JIA subtype within our data; however, it
was not felt either of these variables affected the themes
expressed or data as a whole in a negative manner. A lar-
ger study would be valuable to explore whether gender or
JIA subtype may influence the reported experience of bio-
logic therapies in young people with JIA. The fact that the
patients were known to the researchers and that all the
young people were keen to participate and seemed to
enjoy telling their story, gave the study a positive bias.
Conclusions
This study has highlighted areas where there is a distinct
lack of available literature and where further work is
needed to fully assist young people with JIA. Future studies
of the paediatric rheumatology community are warranted;
specifically concerning young people’s lived experiences of
JIA and their expectations and experiences of taking a bio-
logical therapy. It is important also to raise the profile of
JIA in young people, so it is not seen as a disease only of
the elderly, possibly by getting young people themselves to
be involved in promoting awareness of JIA in young people
and thus educating those around them.
Having JIA as a young person can present many chal-
lenges. The findings from this study can aid the health-
care professional to have a deeper insight into these and,
through this, to be able to offer improved support, edu-
cation and earlier intervention before these issues be-
come a concern. As highlighted earlier, young people’s
perception of their JIA is an area where there is little
published research. This study has specifically focused
on young people with severe arthritis defined by the
need for anti-TNF therapy, therefore this paper is an en-
capsulation of a very specific cohort of young people;
those aged between 10–13 years old, seen in one tertiary
institution, with severe arthritis, and receiving a particu-
lar therapy. Whilst this limits the generalisability of the
findings and requires the researcher to be transparent
and make this clear to the reader, it does not detract
from the need to ask young people their story and for
young people to tell it.
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